Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;10(4):794-802.
doi: 10.1002/jcsm.12431. Epub 2019 Apr 29.

Impact of preoperative body compositions on survival following resection of biliary tract cancer

Affiliations

Impact of preoperative body compositions on survival following resection of biliary tract cancer

Seung Bae Yoon et al. J Cachexia Sarcopenia Muscle. 2019 Aug.

Abstract

Background: Although surgical resection is the only potentially curative treatment for biliary tract cancer, the prognosis remains poor after a major operation such as pancreatoduodenectomy or hepatectomy. We aimed to investigate the impact of preoperative body compositions on long-term survival of patients undergoing resection of biliary tract cancer.

Methods: We analysed data of patients diagnosed with biliary tract cancer who underwent surgery from 2009 to 2015. Skeletal muscle area, skeletal muscle radiation attenuation, and visceral and subcutaneous adipose tissue areas were measured from the computed tomography images at L3 vertebral levels obtained before resection of cancer. Patients were divided into two groups based on the sex-specific median values for each parameter, and long-term survival was compared between the groups.

Results: A total of 371 patients (women, 39.6%; mean age, 66.2 ± 9.6 years) were finally included in the analysis. Patients with low skeletal muscle index (SMI) had significantly shorter median survival than those with high SMI (29 vs. 39 months; P = 0.026). Patients with low skeletal muscle attenuation (SMA) also showed reduced survival compared with those with high SMA (median survival 25 vs. 60 months; P = 0.002). Combining these two factors, survival was highest in the high SMI/high SMA group (reference) and lowest in the low SMI/low SMA group (hazard ratio, 2.18; 95% confidence interval, 1.44-3.30). Visceral and subcutaneous adipose tissue areas were not associated with long-term survival.

Conclusions: Low SMI and low SMA on computed tomography scan have a negative impact on survival after resection of biliary tract cancer. They can be used in preoperative risk assessment to assist in treatment decision making.

Keywords: Biliary tract cancer; Muscle attenuation; Sarcopenia; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests.

Figures

Figure 1
Figure 1
(A) Overall survival curves after operation according to skeletal mass index. (B) Overall survival curves after operation according to skeletal mass attenuation. (C) Overall survival curves after operation according to visceral adipose tissue index. (D) Overall survival curves after operation according to subcutaneous adipose tissue index. (E) Disease‐free survival curve after operation according to skeletal mass index. (F) Disease‐free survival curve after operation according to skeletal mass attenuation.
Figure 2
Figure 2
Overall survival curves in relation to combined preoperative skeletal mass index (SMI) and skeletal muscle attenuation (SMA).

Similar articles

Cited by

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29. - PubMed
    1. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971‐2001. Br J Cancer 2006;94:1751–1758. - PMC - PubMed
    1. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence‐based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 2009;208:134–147. - PubMed
    1. Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science 2013;104:1211–1216. - PMC - PubMed
    1. Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC‐IHCC‐2009 Study Group. Cancer 2011;117:2170–2177. - PubMed

Publication types

LinkOut - more resources